Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: A phase 1 dose-fi nding safety and tolerability trial

The Lancet Haematology

Volumn 1, Issue 3, 2014, Pages e95-e103

  Minniti, Caterina P ^a   Gorbach, Alexander M ^c   Xu, Dihua ^a   Hon, Yuen Yi ^b   Delaney, Kara Marie ^a   Seidel, Miles ^c   Malik, Nitin ^c   Peters Lawrence, Marlene ^a   Cantilena, Carly ^a   Nichols, James S ^a   Mendelsohn, Laurel ^a   Conrey, Anna ^a   Grimes, George ^b   Kato, Gregory J ^a,d,e  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Clinical Center Pharmacy Department   (United States)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYUREA; METHEMOGLOBIN; PROTEIN; SODIUM NITRITE;

ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DOPPLER FLOWMETRY; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOTENSION; LEG ULCER; LEUKOCYTE COUNT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SKIN BLOOD FLOW; VISUAL ANALOG SCALE; WOUND HEALING;

EID: 84922031978     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(14)00019-2     Document Type: Article

References (38)

1. Minniti CP, Taylor JG VI, Hildesheim M, et al. Laboratory and echocardiography markers in sickle cell patients with leg ulcers. Am J Hematol 2011; 86: 705-08.
2. Marti-Carvajal AJ, Knight-Madden JM, Martinez-Zapata MJ. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database Syst Rev 2012; 11: CD008394.
3. Baum KF, MacFarlane DE, Maude GH, Serjeant GR. Topical antibiotics in chronic sickle cell leg ulcers. Trans R Soc Trop Med Hyg 1987; 81: 847-49.
4. Serjeant BE, Harris J, Thomas P, Serjeant GR. Propionyl-L-carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study. J Am Acad Dermatol 1997; 37: 491-93.
5. Serjeant GR, Howard C. Isoxsuprine hydrochloride in the therapy of sickle cell leg ulceration. West Indian Med J 1977; 26: 164-66.
6. La Grenade L, Thomas PW, Serjeant GR. A randomized controlled trial of solcoseryl and duoderm in chronic sickle-cell ulcers. West Indian Med J 1993; 42: 121-23.
7. Wethers DL, Ramirez GM, Koshy M, et al. Accelerated healing of chronic sickle-cell leg ulcers treated with RGD peptide matrix. RGD Study Group. Blood 1994; 84: 1775-79.
8. McMahon L, Tamary H, Askin M, et al. A randomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol 2010; 151: 516-24.
9. Delaney KM, Axelrod KC, Buscetta A, et al. Leg ulcers in sickle cell disease: current patterns and practices. Hemoglobin 2013; 37: 325-32.
10. Dejam A, Hunter CJ, Tremonti C, et al. Nitrite infusion in humans and nonhuman primates: endocrine eff ects, pharmacokinetics, and tolerance formation. Circulation 2007; 116: 1821-31.
11. Mack AK, McGowan VR, Tremonti CK, et al. Sodium nitrite promotes regional blood fl ow in patients with sickle cell disease: a phase I/II study. Br J Haematol 2008; 142: 971-78.
12. Greenway FL, Predmore BL, Flanagan DR, et al. Single-dose pharmacokinetics of diff erent oral sodium nitrite formulations in diabetes patients. Diabetes Technol Ther 2012; 14: 552-60.
13. Tucker AT, Pearson RM, Cooke ED, Benjamin N. Eff ect of nitricoxide- generating system on microcirculatory blood fl ow in skin of patients with severe Raynaud's syndrome: a randomised trial. Lancet 1999; 354: 1670-75.
14. Phillips R, Adjei O, Lucas S, Benjamin N, Wansbrough-Jones M. Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides. Antimicrob Agents Chemother 2004; 48: 2866-70.
15. Shiva S, Gladwin MT. Nitrite mediates cytoprotection after ischemia/reperfusion by modulating mitochondrial function. Basic Res Cardiol 2009; 104: 113-19.
16. Schwentker A, Billiar TR. Nitric oxide and wound repair. Surg Clin North Am 2003; 83: 521-30.
17. Luo JD, Chen AF. Nitric oxide: a newly discovered function on wound healing. Acta Pharmacol Sin 2005; 26: 259-64.
18. Schwentker A, Vodovotz Y, Weller R, Billiar TR. Nitric oxide and wound repair: role of cytokines? Nitric Oxide 2002; 7: 1-10.
19. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997; 99: 2818-25.
20. Bulgrin JP, Shabani M, Chakravarthy D, Smith DJ. Nitric-oxide synthesis is suppressed in steroid-impaired and diabetic wounds. Wounds 1995; 7: 48-57.
21. Kirk SJ, Hurson M, Regan MC, et al. Arginine stimulates woundhealing and immune function in elderly human-beings. Surgery 1993; 114: 155-60.
22. Contreras DL, Robles HV, Romo E, Rios A, Escalante B. The role of nitric oxide in the post-ischemic revascularization process. Pharmacol Ther 2006; 112: 553-63.
23. Jones ML, Ganopolsky JG, Labbe A, Wahl C, Prakash S. Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices. Appl Microbiol Biotechnol 2010; 88: 401-07.
24. Tousoulis D, Kampoli AM, Papageorgiou CTN, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012; 10: 4-18.
25. Gladwin MT, Shelhamer JH, Schechter AN, et al. Role of circulating nitrite and S-nitrosohemoglobin in the regulation of regional blood fl ow in humans. Proc Natl Acad Sci USA 2000; 97: 11482-87.
26. Trent JT, Kirsner RS. Leg ulcers in sickle cell disease. Adv Skin Wound Care 2004; 17: 410-16.
27. King SB. N-hydroxycarbamide and acyl nitroso compounds as nitroxyl (HNO) and nitric oxide (NO) donors. Curr Top Med Chem 2005; 5: 665-73.
28. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxycarbamide induces the eNOS-cGMP pathway in endothelial cells. Blood 2006; 108: 184-91.
29. Oplander C, Volkmar CM, Paunel-Gorgulu A, et al. Dermal application of nitric oxide releasing acidifi ed nitrite-containing liniments signifi cantly reduces blood pressure in humans. Nitric Oxide 2012; 26: 132-40.
30. Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med 1997; 102: 171-77.
31. Serjeant GR, Serjeant BE, Mohan JS, Clare A. Leg ulceration in sickle cell disease: medieval medicine in a modern world. Hematol Oncol Clin North Am 2005; 19: 943-56, viii-ix.
32. Phillips TJ, Machado F, Trout R, Porter J, Olin J, Falanga V. Prognostic indicators in venous ulcers. J Am Acad Dermatol 2000; 43: 627-30.
33. Halabi-Tawil M, Lionnet F, Girot R, Bachmeyer C, Levy PP, Aractingi S. Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. Br J Dermatol 2008; 158: 339-44.
34. Upton D, Andrews A. Sleep disruption in patients with chronic legulcers. J Wound Care 2013; 22: 389-390, 392, 394.
35. Hareendran A, Bradbury A, Budd J, et al. Measuring the impact of venous leg ulcers on quality of life. J Wound Care 2005; 14: 53-57.
36. Kroncke KD, Fehsel K, Kolb-Bachofen V. Nitric oxide: cytotoxicity versus cytoprotection-how, why, when, and where? Nitric Oxide 1997; 1: 107-20.
37. Bolanos JP, Almeida A, Stewart V, et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 1997; 68: 2227-40.
38. Sen CK, Gordillo GM, Roy S, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 2009; 17: 763-71.